The Indian Pharmaceutical Alliance (IPA) has revealed $15 million expenditure to build a dedicated pharmaceutical quality institute in Ahmedabad.
Cipla partners with Pfizer to exclusively market five established brands in India, strengthening acute therapy presence and expanding patient access through a nationwide distribution network.
Alembic Pharmaceuticals Limited has received final approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for travoprost ophthalmic solution USP, 0.004%. The product is indicated for the reductio...
The summit commenced with a welcome address by Rajesh Khubchandani, Co-Founder & Managing Director, Team Marksmen Network, who emphasized, “As we start this journey, we have seen a lot of narratives and stories being told. The way a select few organi
Odisha has declared a policy on drugs and medical equipment to bring investments of 25000 crore by 2030. The policy reflects the desire of the state in turning into a large life-sciences hub in eastern India. It was unveiled during the Odisha...
Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals, has signed an exclusive licensing and distribution agreement with Jiangsu Hansoh Pharmaceutical Group. The agreement is for Aumolertinib, a third-generation...
Biocon launches its GLP-1 drug Liraglutide in the Netherlands, entering Europe with branded diabetes and obesity therapies, strengthening its GLP-1 and biologics portfolio.
.png)
Lupin Manufacturing Solutions (LMS), a subsidiary of Lupin Limited, announced a major strategic alliance today with PolyPeptide Group AG, marking a significant move in the expanding peptide market. The long-term partnership aims to build...
Glenmark Pharmaceuticals announced today that its U.S. subsidiary will roll out Leucovorin Calcium for Injection USP, 350 mg/vial in December 2025. The drug is a single-dose vial and is both bioequivalent and therapeutically equivalent to...
Cipla Limited has introduced Yurpeak (tirzepatide) in India, a once?weekly injectable therapy aimed at managing obesity and type?2 diabetes mellitus. After approval by DCGI, the company will market and sell Yurpeak the second brand of tirzepatide...
.jpg)
, CDSCO.jpg)